10-Q: Intorio Corp. Reports Q1 2025 Results: Focus Shifts to Functional Medicine Under New Leadership

Intorio Corp. reports a net loss for Q1 2025 and outlines a new business direction focusing on functional medicine under new leadership following a major ownership change.

Summary

• Intorio Corp. reported its financial results for the quarter ended May 31, 2024.
• The company incurred a net loss of $1,918 for the quarter, compared to a net loss of $9,877 for the same period in the previous year.
• Revenue for the quarter was $0, compared to $1,350 in the prior year.
• Operating expenses were $921, a significant decrease from $11,227 in the same quarter of the previous year.
• A major ownership change occurred on May 16, 2024, with a new CEO and director appointed.
• The company is shifting its business focus to functional medicine and plans to change its name to REDOX International Group.
• The company's accumulated deficit as of May 31, 2024, was $79,061.
• The company has identified a need for additional capital to continue as a going concern.
• As of May 31, 2024, the company had $0 of cash and cash equivalents.

Sentiment

Score: 3

Explanation: The sentiment is low due to the company's financial difficulties, going concern uncertainty, and ineffective disclosure controls, despite the potential of the new business strategy.

Positives

• The net loss decreased significantly from $9,877 in Q1 2023 to $1,918 in Q1 2024.
• Operating expenses decreased substantially from $11,227 to $921 year-over-year.
• The company is focusing on functional medicine, which could present new growth opportunities.
• Conversion of $54,160 debt to equity improved the company's capital structure.

Negatives

• The company reported $0 in revenue for the quarter ended May 31, 2024.
• The company has an accumulated deficit of $79,061 as of May 31, 2024.
• The company's auditors have raised substantial doubt about its ability to continue as a going concern.
• The company's disclosure controls and procedures were deemed ineffective as of May 31, 2024.
• The company had $0 of cash and cash equivalents as of May 31, 2024.

Risks

• The company's ability to continue as a going concern is uncertain due to its accumulated deficit and lack of revenue.
• The company needs to raise additional capital, and there is no guarantee it will be able to do so on acceptable terms.
• The company's new business strategy focused on functional medicine may not be successful.
• The company's disclosure controls and procedures are not effective, which could lead to inaccurate financial reporting.
• The company has no employees other than its officer and director, which could limit its ability to execute its business plan.

Future Outlook

The company plans to focus on functional medicine and change its name to REDOX International Group; management anticipates additional increases in operating expenses and capital expenditures and expects to fund working capital requirements through existing funds and further issuances of securities.

Management Comments

• Management plans to obtain additional capital resources by obtaining capital from management and significant shareholders and seeking third-party equity and/or debt financing.
• Management cannot provide any assurance that the Company will be successful in accomplishing any of its plans.

Industry Context

The shift to functional medicine aligns with a growing trend in healthcare that emphasizes personalized and preventative care; the company aims to capitalize on the increasing demand for alternative and holistic approaches to health management.

Comparison to Industry Standards

• It is difficult to compare Intorio Corp.'s results to industry standards due to its early stage and recent shift in business strategy.
• Companies in the functional medicine space, such as Parsley Health and Cleveland Clinic's Center for Functional Medicine, have demonstrated the potential for growth in this market.
• However, Intorio Corp. faces significant challenges in establishing itself as a competitor given its limited resources and lack of established brand recognition.

Management Changes

Related Party Transactions

• From inception through May 16, 2024, the Company previous sole officer and director loaned the Company $ 54,160 to pay for incorporation costs and operating expenses.
• On August 12, 2024, a related party loaned the Company $2,250 to pay for operating expense.

Stakeholder Impact

• Shareholders face significant risk due to the company's financial instability and need for additional capital.
• Employees (currently only the officer and director) are impacted by the company's uncertain future.
• Customers may be affected by the shift in business strategy to functional medicine.
• Creditors face increased risk due to the company's going concern uncertainty.

Next Steps

• The company plans to change its name to REDOX International Group.
• The company intends to introduce functional medicine laboratory testing items.
• The company will seek additional funding through equity or debt financing.

Key Dates

Keywords

functional medicine, REDOX International Group, going concern, net loss, Intorio Corp, financial results, ownership change